Dr. Williams previously worked in the same capacity at Osiris Therapeutics, according to a news release. She is a fellow in the American Institute for Medical and Biological Engineering.
“Michelle has been a thought leader in regenerative medicine for two decades,” Randy Mills, PhD, CEO of Aziyo, said in the release. “She has a track record of consistently developing commercially successful products, including Osteocel, the world’s first stem cell product with cumulative sales of over $1 billion. We believe her ability to develop great products, backed by strong science and through efficient use of capital, will create significant value for Aziyo.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
